In breast cancer tumours and cell lines, we have reported that the highly variable abundance of phospho‐CDK4 signals the presence or absence of active CDK4 targeted by CDK4/6i, which was associated with the sensitivity or insensitivity of tumour cells to palbociclib [51]. Here, CDK4 is linked to neoplasm.